spacer
home > ebr > winter 2002 > crossbreeding and commercial consolidation in the uppsala biotech cluster
PUBLICATIONS
European Biopharmaceutical Review

Crossbreeding and Commercial Consolidation in the Uppsala Biotech Cluster

The Uppsala region has undergone a remarkable transformation in the biomedical area since the mid-1990s. The city, which lies about 70 kilometres north of the Swedish capital Stockholm, has seen a virtual explosion of research projects, business initiatives, entrepreneurial activity, new companies and industrial investment in the biotechnology and life science sectors.

Tradition, cutting edge research, access to human and financial capital, as well as a growing global market demanding solutions relying on biotech research and development, has created what has become known as the 'Uppsala Phenomenon'. "Today there are about 140 life science companies in Uppsala, of which more than 50 are biotech companies.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Per Odebrant, Freelance Science and Business Journalist
Per Odebrant is a Swedish freelance journalist specialising in science and business issues. He has a particular focus on applications of biotechnology, information technology and materials science. He also writes on matters concerning management, industrial organisation and intellectual capital. Per contributes to various national dailies, national and international magazines, and trade journals. He has also been a Consultant Project Manager to the Swedish Government's Information Technology Commission.
Per holds a degree in Philosophy/Linguistics from the University of Lund and has authored three novels. He was commissioned to write this article by STUNS, the Foundation for Collaboration between the Universities in Uppsala, the Business Community and Society.

spacer
Per Odebrant
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

WuXi STA and Dizal Pharmaceutical Sign CMC Development and Manufacturing Agreement

STA Pharmaceutical Co., Ltd., (WuXi STA) a subsidiary of WuXi AppTec and Dizal Pharmaceutical, a biotechnology company, announce a strategic partnership. Under the terms of the collaboration, WuXi STA will become the preferred CDMO partner of Dizal Pharmaceutical for GMP production, providing integrated CMC (Chemical, manufacturing and Control) process research and manufacturing services from API to drug product.
More info >>

White Papers

Planning the Execution of a Viral Clearance Study

Eurofins BioPharma Product Testing

Viral clearance studies are a necessary component of any regulatory submission for clinical trials or commercial product approval for all biopharmaceutical products. These studies are performed to evaluate the capability of the purification process to remove or inactivate viruses that could potentially contaminate the starting material. They are complex studies that require substantial financial and personnel resources, as well as specialized scientific expertise to perform. As such, viral clearance studies are often performed at a qualified contract testing laboratory rather than in-house. When multiple parties are involved in this process, clear communication and a comprehensive understanding of the approach and timeline is critical.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement